Abstract:Background: Whether bone markers have prognostic value in patients with bone metastases is unknown. We investigated this question in patients with bone metastases secondary to prostate cancer and to non-small-cell lung cancer (NSCLC) and other solid tumors assigned to the placebo arms of two phase III trials of zoledronic acid. Methods: Levels of the urinary bone resorption marker N-telopeptide and the serum bone formation marker bone-specific alkaline phosphatase were assessed every 3 months for patients with prostate cancer (n = 203) or NSCLC or other solid tumors (n = 238) and were categorized as low or high. Patients were monitored for skeletal-related events, bone disease progression, and death. The relative risks (RRs) and 95% confidence intervals (Cis) for these outcomes were estimated for patients with high versus low levels of each marker using intensity-based multiple event and Cox regression models. All statistical tests were two-sided. Results: In each disease group and overall, high levels of each marker at the beginning of the study were statistically significantly associated with an increased risk of negative outcomes. Use of recent marker assessments as time-dependent covariates gave even greater prognostic significance. High N-telopeptide levels were a stronger prognostic indicator of negative outcomes than bone-specific alkaline phosphatase levels. In recent assessments, patients with high N-telopeptide levels had an increased relative risk of skeletal-related events (prostate cancer, RR = 3.25, 95 % CI = 2.26 to 4.68, P < .001; NSCLC and other solid tumors, RR = 1.79, 95% CI = 1.15 to 2.79, P = .010), disease progression (prostate cancer, RR = 2.02, 95% CI = 1.48 to 2.74, P < .001; NSCLC and other solid tumors, RR = 1.91, 95% CI = 1.16 to 3.15, P = .011), and death (prostate cancer, RR = 4.59, 95% CI 2.82 to 7.46, P < .001; NSCLC and other solid tumors, RR 2.67,95% CI = 1.85 to 3.85, P < .001) compared with patients with low N-telopeptide levels. Conclusions: Baseline and recent bone marker levels were predictive of negative clinical outcomes in patients with bone metastases secondary to prostate cancer and to NSCLC and other solid tumors. N-telopeptide levels were more consistent prognostic indicators than bone-specific alkaline phosphatase for all tumor types, reflecting the key role of osteolysis in the development of skeletal complications.

The association between serum albumin and alkaline phosphatase in cancer patients

The Association Between Albumin and Mortality in Patients with Acute Kidney Injury: a Retrospective Observational Study

Clinical significance of preoperative albumin and alkaline phosphatase in colorectal cancer: a systematic review and meta-analysis

Predictive value of serum albumin levels on cancer survival: a prospective cohort study

Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients

Serum albumin level is associated with mortality and hospital stays: A real-world data analysis

High Alkaline Phosphatase and Low Intact Parathyroid Hormone Associate with Worse Clinical Outcome in Peritoneal Dialysis Patients

Nonlinear association of alkaline phosphatase-to-albumin ratio with all-cause and cancer mortality: Evidence from NHANES 2005 to 2016

Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD.

Correlation between initial alkaline phosphatase levels and overall survival in newly diagnosed multiple myeloma patients

Albumin-to-alkaline phosphatase ratio as a promising indicator of prognosis in human cancers: is it possible?

Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer.

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients with Bone Metastases Receiving the Bisphosphonate Zoledronic Acid.

Association between pre‐diagnostic serum albumin and cancer risk: Results from a prospective population‐based study

Prognostic Significance of Serum Lactic Acid, Lactate Dehydrogenase, and Albumin Levels in Patients with Metastatic Colorectal Cancer

Prognostic role of pre‐treatment serum albumin in patients with nasopharyngeal carcinoma: A meta‐analysis and systematic review

Serum albumin is associated with the inherent property of acute myeloid leukemia and correlates with patient outcomes

The Prognostic Value of Serum Albumin to Globulin Ratio in Patients with Breast Cancer: A Retrospective Study

Association between serum alkaline phosphatase and clinical prognosis in patients with acute liver failure following cardiac arrest: a retrospective cohort study

Associations of serum alkaline phosphatase level with all-cause and cardiovascular mortality in the general population

Bone Turnover Markers As Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors